ECSP055854A - Uso de una asociación que contiene un inhibidor no nucleósido de la transcriptasa inversa (nnrti) con un inhibidor de citocromo p450, tales como los inhibidores de la proteasa - Google Patents

Uso de una asociación que contiene un inhibidor no nucleósido de la transcriptasa inversa (nnrti) con un inhibidor de citocromo p450, tales como los inhibidores de la proteasa

Info

Publication number
ECSP055854A
ECSP055854A EC2005005854A ECSP055854A ECSP055854A EC SP055854 A ECSP055854 A EC SP055854A EC 2005005854 A EC2005005854 A EC 2005005854A EC SP055854 A ECSP055854 A EC SP055854A EC SP055854 A ECSP055854 A EC SP055854A
Authority
EC
Ecuador
Prior art keywords
inhibitor
nnrti
cytrochrome
protease inhibitors
reverse transcript
Prior art date
Application number
EC2005005854A
Other languages
English (en)
Inventor
Michael Cordingley
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of ECSP055854A publication Critical patent/ECSP055854A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método mejorado para utilizar una NNRTI en el tratamiento de infección por VIH-1, una cantidad terapéuticamente eficaz de dicha NNRTI o una sal farmacéuticamente aceptable de la misma y una cantidad de un inhibidor del citocromo P450 que es suficiente para elevar, reforzar o ampliar las concentraciones en plasma de dicha NNRTI.
EC2005005854A 2002-12-16 2005-06-15 Uso de una asociación que contiene un inhibidor no nucleósido de la transcriptasa inversa (nnrti) con un inhibidor de citocromo p450, tales como los inhibidores de la proteasa ECSP055854A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43369002P 2002-12-16 2002-12-16

Publications (1)

Publication Number Publication Date
ECSP055854A true ECSP055854A (es) 2006-01-16

Family

ID=32595224

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005854A ECSP055854A (es) 2002-12-16 2005-06-15 Uso de una asociación que contiene un inhibidor no nucleósido de la transcriptasa inversa (nnrti) con un inhibidor de citocromo p450, tales como los inhibidores de la proteasa

Country Status (20)

Country Link
US (2) US20040152625A1 (es)
EP (1) EP1575595A1 (es)
JP (1) JP2006511538A (es)
KR (1) KR20050085681A (es)
CN (1) CN1726041A (es)
AU (1) AU2003296647A1 (es)
BR (1) BR0317095A (es)
CA (1) CA2510143A1 (es)
EA (1) EA200500894A1 (es)
EC (1) ECSP055854A (es)
HR (1) HRP20050557A2 (es)
IL (1) IL169099A0 (es)
MX (1) MXPA05005773A (es)
NO (1) NO20053455L (es)
NZ (1) NZ541187A (es)
PL (1) PL376900A1 (es)
RS (1) RS20050461A (es)
UA (1) UA81003C2 (es)
WO (1) WO2004054586A1 (es)
ZA (1) ZA200502947B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
ES2539527T3 (es) * 2005-04-27 2015-07-01 Taimed Biologics, Inc. Método para mejorar la farmacocinética de los inhibidores de las proteasas y de los precursores de los inhibidores de las proteasas
AU2006319716B2 (en) 2005-11-30 2012-02-02 Taimed Biologics, Inc. Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
CN1907138B (zh) * 2006-08-11 2011-01-12 华南师范大学 一种沙田柚子汁提取物及其提取方法和应用
JP5401652B2 (ja) 2006-09-21 2014-01-29 タイメッド バイオロジクス インコーポレイテッド プロテアーゼ阻害剤
NZ595280A (en) 2009-02-27 2013-11-29 Enanta Pharm Inc Hepatitis c virus inhibitors
JP5523552B2 (ja) 2009-04-25 2014-06-18 エフ．ホフマン−ラ ロシュ アーゲー 薬物動態を改善する方法
EP2429568B1 (en) 2009-05-13 2016-08-17 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
WO2011081918A1 (en) 2009-12-14 2011-07-07 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020212395A1 (en) 2019-04-16 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5539122A (en) * 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
CA2285577A1 (en) * 1997-04-07 1998-10-15 Triangle Pharmaceuticals, Inc. Compositions containing mkc-442 in combination with other antiviral agents
JP2002528502A (ja) * 1998-11-04 2002-09-03 ファルマシア・アンド・アップジョン・カンパニー チプラナビルの薬物動態を改善する方法
US6391919B1 (en) * 2000-01-12 2002-05-21 Bristol-Myers Squibb Pharma Company Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors
TWI270547B (en) * 2000-06-16 2007-01-11 Boehringer Ingelheim Ca Ltd Non-nucleoside reverse transcriptase inhibitors
WO2004085437A1 (en) * 2002-09-19 2004-10-07 Boehringer Ingelheim (Canada) Ltd. Non-nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
US20040152625A1 (en) 2004-08-05
HRP20050557A2 (en) 2006-05-31
RS20050461A (en) 2007-08-03
CA2510143A1 (en) 2004-07-01
EA200500894A1 (ru) 2006-02-24
ZA200502947B (en) 2008-01-30
MXPA05005773A (es) 2005-08-16
NO20053455L (no) 2005-08-10
IL169099A0 (en) 2007-07-04
BR0317095A (pt) 2005-10-25
AU2003296647A1 (en) 2004-07-09
US20080096832A1 (en) 2008-04-24
UA81003C2 (en) 2007-11-26
EP1575595A1 (en) 2005-09-21
NZ541187A (en) 2007-12-21
KR20050085681A (ko) 2005-08-29
PL376900A1 (pl) 2006-01-09
WO2004054586A1 (en) 2004-07-01
JP2006511538A (ja) 2006-04-06
CN1726041A (zh) 2006-01-25

Similar Documents

Publication Publication Date Title
ECSP055854A (es) Uso de una asociación que contiene un inhibidor no nucleósido de la transcriptasa inversa (nnrti) con un inhibidor de citocromo p450, tales como los inhibidores de la proteasa
ES2524458T3 (es) DNasa para el tratamiento de la subfertilidad masculina
CO5640076A2 (es) Composicion farmaceutica que comprende un inhibidor de ibat para el tratamiento o profilaxis del estreñimiento
PE20060149A1 (es) Formulacion farmaceutica para tratar la infeccion por vih
BRPI0415935A (pt) combinações para tratamento de hcv
ECSP045223A (es) Composiciones farmacéuticas para inhibidores de proteasa viral de la hepatitis c
AR043356A1 (es) Dispositvo de liberacion sostenida para la administracion ocular de inhibidores de la anhidrasa carbonica y uso de inhibidores de la anhidrasa carbonica para su preparacion
ECSP11010948A (es) Inhibidores de las enzimas de proteína cinasa activadas por
ECSP055738A (es) PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL
NI201000136A (es) Inhibidores macrocíclicos de serina proteasa.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
DK0871465T3 (da) Anvendelse af ritonavir (ABT-538) til at forbedre farmakokinetikken af lægemidler, som metaboliseres af cytochrom P450, i en metode til behandling af AIDS
NO20090322L (no) 6-(heterosykel-substituert benzyl)-4-oksoquinolin forbindelse samt anvendelse av det samme som IIIV integrave inhibitor
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
PE20220017A1 (es) Inhibidores del kcnt1 y metodos de uso
NO20063483L (no) Therapeutic combinations
CL2023000524A1 (es) Compuestos fosfolípidos y usos de los mismos
AR047880A1 (es) COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS
CL2023001201A1 (es) Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados
UY26648A1 (es) Inhibidores de vasopeptidasa para tratar hipertensión sistólica aislada
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
NO20083916L (no) Proteasom- eller UPS-inhibitor for behandling av infeksjoner med influensavirus
AR013758A1 (es) Terapia de combinacion para el tratamiento de sida.
AR083780A1 (es) Composicion farmaceutica para tratar infecciones del hcv
CL2022003039A1 (es) Inhibidores de il4i1 y métodos de uso.